Financial Performance - Total global revenues reached $1.5 billion and $5.3 billion for the fourth quarter and full year 2025, representing increases of 33% and 40% from the prior-year periods[5] - BRUKINSA (zanubrutinib) global sales were $1.1 billion and $3.9 billion for the fourth quarter and full year 2025, reflecting growth of 38% and 49% compared to the prior-year periods[11] - Adjusted net income for the fourth quarter was $225 million, a 1297% increase from the prior-year period, and $918 million for the full year, a 1771% increase[3] - GAAP net income for the fourth quarter was $67 million, an increase of $218 million, and $287 million for the full year, an increase of $932 million over the prior-year periods[10] - BeOne's product revenue for Q4 2025 reached $1,476,442, a 32.2% increase from $1,118,035 in Q4 2024[32] - Total revenues for the full year 2025 were $5,343,033, up 40.4% from $3,810,241 in 2024[32] - GAAP net income for Q4 2025 was $66,502, compared to a loss of $151,881 in Q4 2024, while full year 2025 net income was $286,933, an improvement from a loss of $644,786 in 2024[38] - Adjusted earnings per share (EPS) for Q4 2025 was $0.16, significantly up from $0.01 in Q4 2024, and full year adjusted EPS was $0.65 compared to a loss of $0.04 in 2024[39] Cash Flow and Financial Position - Free cash flow for the fourth quarter was $380 million, an increase of $397 million over the prior-year period, and $942 million for the full year, an increase of $1.6 billion[13] - The company had cash, cash equivalents, and restricted cash of $4,609,647 as of December 31, 2025, compared to $2,638,747 in 2024[34] - Free cash flow for Q4 2025 was $379,825, a recovery from a negative cash flow of $17,320 in Q4 2024, with full year free cash flow at $941,741 compared to a loss of $633,294 in 2024[40] Expenses and Investments - Research and development expenses for the fourth quarter were $615 million, a 14% increase from the prior-year period, and $2.1 billion for the full year, a 10% increase[8] - Selling, general and administrative expenses for the fourth quarter were $555 million, a 10% increase from the prior-year period, and $2.1 billion for the full year, a 14% increase[9] - Research and development expenses for Q4 2025 were $615,423, up from $542,012 in Q4 2024, indicating increased investment in R&D[32] - Adjusted selling, general and administrative expenses for Q4 2025 were $471,468, compared to $433,059 in Q4 2024, with full year adjusted expenses at $1,743,118, up from $1,549,864 in 2024[38] Guidance and Future Plans - Full year 2026 total revenue guidance is projected to be between $6.2 billion and $6.4 billion, driven by BRUKINSA's leadership position in the U.S. and global expansion[14] - The company plans to submit supplemental Biologics License Applications for TEVIMBRA in the U.S. and China in 1H 2026[24] - BeOne aims to initiate several Phase 3 trials in 2026, including for BRUKINSA and BGB-43395, to expand its oncology pipeline[24] - GAAP operating income guidance for full year 2026 is projected to be between $700,000 and $800,000, with non-GAAP operating income expected to range from $1,400,000 to $1,500,000[41] Asset and Liability Management - Total assets increased to $8,188,573 in 2025 from $5,920,910 in 2024, showing strong growth in the company's financial position[34] - BeOne's total liabilities rose to $3,827,379 in 2025, up from $2,588,688 in 2024, reflecting increased operational scale[34] Profitability and Operational Efficiency - Gross margin as a percentage of global product sales for the fourth quarter and full year 2025 was 90.4% and 87.3%, compared to 85.6% and 84.3% in the prior-year periods[7] - The company reported a GAAP loss from operations of $79,425 in Q4 2024, which improved to a profit of $185,035 in Q4 2025, while full year loss from operations was $568,199 in 2024, improving to a profit of $447,136 in 2025[38] - The impairment of equity investments added $41,410 to the GAAP net income in Q4 2025, compared to $6,838 in Q4 2024, indicating a significant impact on financial results[38] - Adjusted cost of sales for products in Q4 2025 was $137,403, a decrease from $141,288 in Q4 2024, while full year adjusted cost of sales was $643,974, up from $546,653 in 2024[38]
BEIGENE(ONC) - 2025 Q4 - Annual Results